SearchSearch results for: “”

Our Brussels IP/Life Sciences team has authored a booklet on the case-law of the Court of justice of the EU (CJEU) regarding supplementary protection certificates (SPCs).

De Europese Commissie zet in op meer staatssteun voor innovatieve ondernemingen en duurzaamheid. Dit blijkt uit de voorgestelde wijziging van de Algemene groepsvrijstellingsverordening waarover tot 8 december a.s. een consultatie loopt.

On 6 July 2021, the European Commission adopted the much-awaited decision C(2021) 4858 final which provides very useful answers to the questions raised by the European Supervisory Authorities on priority issues relating to the application of the SFDR.

In de nieuwe podcastaflevering van Stibbe Legal Insights spreken Femke van der Voort, gespecialiseerd in intellectueel eigendom, en Paul van der Hulst, mede-eigenaar en managing director van MoviĜo, over het beschermen van intellectuele eigendomsrechten.

The outbreak of the Covid-19 crisis has been officially acknowledged as a pandemic and public health crisis. In response, the Belgian authorities have decided to proceed with the grant of temporary authorisations for certain biocidal product types.

This blogpost explores the evolving legal landscape governing AI in life sciences, with a focus on medical device regulation, data protection and intellectual property.

The Litigation Chamber of the Belgian DPA confirms that, in the absence of an existing legal basis, it is not possible for an employer, in this case a hospital, to make the recruitment of a person conditional on the fact that he/she has been vaccinated.

On 24 May 2024, the European Banking Authority (EBA) published a report on virtual IBAN (vIBANs) in which the EBA set outs characteristics and use cases of vIBANs and comments on identified risks associated with this development in the payments market.

On 9 July 2020, the Grand Chamber of the CJEU ruled on the interpretation of Article 3(d) of Regulation 469/2009 concerning the supplementary protection certificate (CCP) for medicinal products.

A recent report of the AFM underlines its focus on monitoring SFDR compliance, signals tightening enforcement action against those lagging behind, and highlights a new phase of supervisory attention for clear, accurate and reliable SFDR disclosures.

Transition finance provides options for borrowers and issuers who are not able or willing to commit to green and sustainability principles in their financing options, as they are transitioning their businesses onto the path towards a sustainable future.

We publish high-quality legal knowledge and insights on our website on a daily basis. If you would like to be promptly informed about the latest developments within your areas of interest, we invite you to sign up for our Legal Updates.